These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12908659)

  • 1. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.
    Swartz MS; Perkins DO; Stroup TS; McEvoy JP; Nieri JM; Haak DC
    Schizophr Bull; 2003; 29(1):33-43. PubMed ID: 12908659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.
    Keefe RS; Mohs RC; Bilder RM; Harvey PD; Green MF; Meltzer HY; Gold JM; Sano M
    Schizophr Bull; 2003; 29(1):45-55. PubMed ID: 12908660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial.
    Schneider LS; Ismail MS; Dagerman K; Davis S; Olin J; McManus D; Pfeiffer E; Ryan JM; Sultzer DL; Tariot PN
    Schizophr Bull; 2003; 29(1):57-72. PubMed ID: 12908661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies.
    Davis SM; Koch GG; Davis CE; LaVange LM
    Schizophr Bull; 2003; 29(1):73-80. PubMed ID: 12908662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.
    Miller DD; McEvoy JP; Davis SM; Caroff SN; Saltz BL; Chakos MH; Swartz MS; Keefe RS; Rosenheck RA; Stroup TS; Lieberman JA
    Schizophr Res; 2005 Dec; 80(1):33-43. PubMed ID: 16171976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
    Meyer JM; Nasrallah HA; McEvoy JP; Goff DC; Davis SM; Chakos M; Patel JK; Keefe RS; Stroup TS; Lieberman JA
    Schizophr Res; 2005 Dec; 80(1):9-18. PubMed ID: 16125372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are high initial doses of olanzapine required to reduce agitation associated with schizophrenia?
    Townsend MH; Baier MB
    J Clin Psychopharmacol; 2004 Feb; 24(1):95-7. PubMed ID: 14709956
    [No Abstract]   [Full Text] [Related]  

  • 8. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.
    Stroup TS; McEvoy JP; Swartz MS; Byerly MJ; Glick ID; Canive JM; McGee MF; Simpson GM; Stevens MC; Lieberman JA
    Schizophr Bull; 2003; 29(1):15-31. PubMed ID: 12908658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reach of benchmark psychiatric trial results to community-based providers: a case study of CATIE.
    Petersen TJ; Huffman JC; Weiss AP; Blais MA; Andreotti CF; Horwitz MB; Birnbaum RJ
    J Clin Psychiatry; 2008 Jul; 69(7):1081-6. PubMed ID: 18605813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 1():28-33. PubMed ID: 17286525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.
    Jakubovski E; Carlson JP; Bloch MH
    J Clin Psychiatry; 2015 Nov; 76(11):1535-45. PubMed ID: 26581028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
    Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
    Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study.
    Fervaha G; Agid O; Takeuchi H; Foussias G; Remington G
    Eur Neuropsychopharmacol; 2014 Jul; 24(7):1078-85. PubMed ID: 24726579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study.
    Swartz MS; Wagner HR; Swanson JW; Stroup TS; McEvoy JP; Canive JM; Miller DD; Reimherr F; McGee M; Khan A; Van Dorn R; Rosenheck RA; Lieberman JA
    J Nerv Ment Dis; 2006 Mar; 194(3):164-72. PubMed ID: 16534433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of cognition and psychopathology to functional impairment in schizophrenia.
    Mohamed S; Rosenheck R; Swartz M; Stroup S; Lieberman JA; Keefe RS
    Am J Psychiatry; 2008 Aug; 165(8):978-87. PubMed ID: 18450928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis.
    Rabinowitz J; Berardo CG; Bugarski-Kirola D; Marder S
    Schizophr Res; 2013 Nov; 150(2-3):339-42. PubMed ID: 23899997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction: evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond.
    Nasrallah HA
    J Clin Psychiatry; 2007; 68 Suppl 1():3-4. PubMed ID: 17286521
    [No Abstract]   [Full Text] [Related]  

  • 18. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.
    Weiden PJ
    J Clin Psychiatry; 2007; 68 Suppl 1():12-9. PubMed ID: 17286523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meeting everyday challenges: antipsychotic therapy in the real world.
    Gorwood P
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S156-62. PubMed ID: 16872807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case study of SMART attributes: a qualitative assessment of generalizability, retention rate, and trial quality.
    Moodie EE; Karran JC; Shortreed SM
    Trials; 2016 May; 17(1):242. PubMed ID: 27180047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.